source boundary
frontier-owneddeclared
A source record is provenance. It supports a finding only through evidence atoms, extraction spans, and reviewed finding bundles.
frontiers / frontier
Source record
back to sourcessource boundary
frontier-ownedA source record is provenance. It supports a finding only through evidence atoms, extraction spans, and reviewed finding bundles.
finding bindings
record contextFindings bound to this source through source ids, evidence atoms, provenance, or reviewed source-record slots.
evidence atoms
materializedEvidence atoms pin exact spans, measurements, selectors, or curation assertions to the source.
review context
inspectable1 reviewable changes and 0 evaluations are attached through this source or its findings.
Locator and citation
locator
title:Sarnaik et al. J Clin Oncol 2021 (lifileucel C-144-01); FDA approval 2024
imported
2026-05-09T22:24:32.461826+00:00
extraction mode
manual_curation
authors
agent:immuno-research-bot-2026-05-09
Caveats
No source-specific caveats are recorded.
Tumor-infiltrating lymphocyte (TIL) therapy with lifileucel produced durable responses in advanced melanoma post anti-PD-1 progression; FDA approved 2024 for unresectable/metastatic melanoma. The class extends adoptive-cell therapy beyond engineered receptors into autologous polyclonal repertoires.
events
vev_b9e38065d612ae27finding.assertedManual finding added to frontier state
agent:immuno-research-bot-2026-05-09 · 2026-05-09
reviewable changes
vpr_d1b7c2cbc7c8df22finding.addManual finding added to frontier state
applied · agent:immuno-research-bot-2026-05-09 · 2026-05-09
evaluations
No evaluation rows are attached.